5:39 PM
 | 
Sep 03, 2013
 |  BC Extra  |  Clinical News

CV data published for DPP-4 inhibitors Nesina, Onglyza

The New England Journal of Medicine published data from cardiovascular outcomes trials for diabetes drugs Nesina alogliptin from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Onglyza saxagliptin from Bristol-Myers Squibb Co. (NYSE:BMY) and partner AstraZeneca plc (LSE:AZN; NYSE:AZN). The data for the oral dipeptidyl peptidase-4 (DPP-4) inhibitors were also presented at the European Society of Cardiology meeting in...

Read the full 300 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >